Last updated: February 23, 2026
What is NDC 47781-0577?
NDC 47781-0577 refers to a specific drug listed under the National Drug Code system. Based on available data, this NDC is associated with Eliquis (apixaban), an oral anticoagulant used to reduce the risk of stroke and blood clots in patients with atrial fibrillation, as well as for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Eliquis is marketed by Bristol-Myers Squibb and Pfizer.
Market Size and Dynamics
Current Market Position
Eliquis has established a leading position in the anticoagulant segment, competing mainly with Xarelto (rivaroxaban) and Pradaxa (dabigatran). In 2022, Eliquis held approximately 31% of the oral anticoagulant market share in the U.S., with annual sales exceeding $9 billion (IQVIA, 2023).
Key Factors Driving Market Growth
- Expanding indications: New approvals, including extended use for prophylaxis in orthopedic surgeries, broaden the target population.
- Rising prevalence of atrial fibrillation: Projected to reach 12 million Americans by 2030.
- Shift from warfarin: Increasing preference for direct oral anticoagulants (DOACs) due to ease of use and fewer monitoring requirements.
- Patent status: Patent exclusivity offers high sales margins until patent expiration.
Patent and Regulatory Status
Eliquis's primary patent expiration occurred in 2031; patent extensions may influence phase-in of generics. The FDA approved its biosimilars, but no biosimilars specifically for Eliquis exist as of 2023. The potential entry of generic versions could significantly impact pricing and market share.
Price Analysis
Current Retail Pricing
Wholesale acquisition costs (WAC) for Eliquis 5 mg tablets are approximately $20-25 per tablet. The average retail price varies by pharmacy and insurance coverage but generally ranges from $10,000 to $12,000 annually per patient for a standard dosing regimen.
| Price Metric |
Value |
Source |
| WAC per tablet |
$20-25 |
GoodRx, 2023 |
| Annual treatment cost |
$10,000 - $12,000 |
IQVIA, 2023 |
| Discounted retail price |
~$8,000 - $10,000 annually |
Outpatient pharmacy data |
Price Trends and Projections
- Short-term (1-2 years): Prices are expected to remain stable due to patent protection and limited generic competition.
- Mid-term (3-5 years): Introduction of generic versions anticipated after 2031 could lead to a 40-60% price reduction.
- Long-term (5+ years): Post-generic entry, prices could drop below $4,000 annually, aligning with generic anticoagulant pricing.
Impact of Biosimilars and Generics
While Eliquis does not currently have generic equivalents, biosimilar development and regulatory pathways may facilitate future lower-cost options. Once patents expire, competitive pressures typically lower prices significantly, as observed with other blockbuster drugs.
Market Trends and Competitive Landscape
Major Competitors
- Xarelto (rivaroxaban): Estimated 36% market share, with similar indications and pricing.
- Pradaxa (dabigatran): Holds approximately 12% market share in the U.S.
- Other anticoagulants: Edoxaban (Savaysa), betrixaban, and warfarin (generic), with warfarin remaining a low-cost alternative.
Regulatory and Policy Factors
- Medicare and private insurers increasingly favor DOACs due to reduced monitoring costs.
- Price negotiations and formulary restrictions influence market access.
- Patent litigations and challenges could alter market exclusivity timelines.
Revenue and Sales Forecasts
| Year |
Projected Global Sales |
Notes |
| 2023 |
$9.6 billion |
Maintains leading market position |
| 2025 |
$11 billion |
Continued growth driven by expanding indications |
| 2030 |
$13 billion |
Peak sales pre-generic entry |
| 2032 |
$4-6 billion |
After patent expiration, assuming generic entry |
Risks and Opportunities
- Risks: Patent litigation delays, regulatory hurdles for biosimilars, price pressure from generics.
- Opportunities: New indications, combination therapies, emerging markets expansion.
Key Takeaways
- NDC 47781-0577 (Eliquis) is a top-selling anticoagulant projected to peak around 2030 with sales surpassing $13 billion globally.
- Patent expiration around 2031 is expected to trigger substantial price reductions, potentially lowering annual treatment costs by over 50%.
- Short-term stability in pricing persists due to patent protections; future price declines depend on generic biosimilar development.
- Market growth is driven by expanding indications, increased prevalence of atrial fibrillation, and shifting prescribing behaviors.
- Competitive pressure from Xarelto remains significant, with both drugs commanding similar market shares and pricing strategies.
References
- IQVIA. (2023). Pharmaceutical market data. [Data set].
- GoodRx. (2023). Eliquis (apixaban) prices and discounts.
- U.S. Food and Drug Administration. (2023). Eliquis approval and patent information.
Note: Data specific to the NDC 47781-0577 is based on the primary drug Eliquis, as no distinct data on formulation variations was available. Price projections assume typical dosing regimens and current market trends.
